Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- INZY
- Price
- 3.99
- Stock movement up
- +0.01 (0.13%)
- Company name
- Inozyme Pharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 256.32M
- Ent value
- 292.32M
- Price/Sales
- 129.72
- Price/Book
- 3.10
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -13.26%
- 3 year return
- -4.07%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-06-22
DIVIDENDS
INZY does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 129.72 |
| Price to Book | 3.10 |
| EV to Sales | 147.93 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 64.24M |
| EPS (TTM) | -1.52 |
| FCF per share (TTM) | -1.44 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.98M |
| Gross profit (TTM) | 1.10M |
| Operating income (TTM) | -99.67M |
| Net income (TTM) | -96.49M |
| EPS (TTM) | -1.52 |
| EPS (1y forward) | -1.57 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 55.92% |
| Operating margin (TTM) | -5043.98% |
| Profit margin (TTM) | -4883.30% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 24.57M |
| Net receivables | 0.00 |
| Total current assets | 140.94M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 143.36M |
| Accounts payable | 2.21M |
| Short/Current long term debt | 46.79M |
| Total current liabilities | 18.34M |
| Total liabilities | 60.57M |
| Shareholder's equity | 82.79M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -91.21M |
| Capital expenditures (TTM) | 150.00K |
| Free cash flow (TTM) | -91.36M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -116.56% |
| Return on Assets | -67.31% |
| Return on Invested Capital | -109.24% |
| Cash Return on Invested Capital | -103.42% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.99 |
| Daily high | 3.99 |
| Daily low | 3.98 |
| Daily Volume | 772K |
| All-time high | 30.20 |
| 1y analyst estimate | 19.56 |
| Beta | 1.54 |
| EPS (TTM) | -1.52 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| INZY | S&P500 | |
| Current price drop from All-time high | -86.79% | -3.04% |
| Highest price drop | -97.28% | -56.47% |
| Date of highest drop | 4 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -72.35% | -11.04% |
| Avg time to new high | 123 days | 12 days |
| Max time to new high | 1206 days | 1805 days |
COMPANY DETAILS
Marketcap
256.32M
Marketcap category
Small-cap
Description
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Employees
59
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner